- Home
- / Crescendo Biologics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Crescendo Biologics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Total Funding
$116.2 M
Revenue
£7.5 M
FY, 2018
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| GBP | FY, 2016 | FY, 2017 | FY, 2018 |
|---|---|---|---|
| Revenue | 758.3K | 1.8M | 7.5M |
| Gross profit | 758.3K | 1.8M | 7.5M |
| Gross profit margin, % | 100.0% | 100.0% | 100.0% |
| Depreciation and amortization | 313.2K | 513.3K | 621.3K |
| EBIT | (5.5M) | (8.1M) | (2.2M) |
| EBIT margin, % | -723.1% | -449.3% | -29.6% |
| Interest income | 31.3K | 48.0K | 99.4K |
| Interest expense | 4.2K | ||
| Pre tax profit | (5.5M) | (10.9M) | (3.0M) |
| Income tax expense | (1.1M) | (1.4M) | (1.2M) |
| Net Income | (4.3M) | (9.5M) | (1.8M) |